



Universiteit
Leiden
The Netherlands

Diagnostic procedures for assessing the severity of alloimmune fetal anemia

Sikkel, E.

Citation

Sikkel, E. (2006, March 2). *Diagnostic procedures for assessing the severity of alloimmune fetal anemia*. Retrieved from <https://hdl.handle.net/1887/4542>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4542>

Note: To cite this publication please use the final published version (if applicable).

Part 1: Chemical approach



Diagnostic accuracy of Δ OD 450
measurements and middle cerebral
artery peak systolic velocity in
the prediction of severe fetal
alloimmune anemia:
a literature review

Esther Sikkel, MD
Frank P.H.A. Vandenbussche, MD, PhD
Dick Oepkes, MD, PhD
Humphrey H.H. Kanhai, MD, PhD

Introduction

The severity of fetal alloimmune anemia can be diagnosed biochemically or sonographically. The biochemical method is based on the fact that hemolysis results in increased bilirubin concentrations in fetal blood and in amniotic fluid.¹ Already in 1956, Bevis found that bilirubin concentrations in amniotic fluid are indicative of the severity of the hemolytic process in fetuses of alloimmunized mothers.² In 1961, Liley proposed amniotic fluid sampling to measure deviation of optical density at 450 nm (Δ OD 450) to predict life-threatening fetal anemia in the third trimester.³

The American College of Obstetricians and Gynecologists (ACOG) still recommends serial amniocentesis in pregnancies at risk, followed by intrauterine transfusion (IUT) or early delivery when Δ OD 450 values are in Liley zone 3 or in the upper third of Liley zone 2 and rising.⁴ Amniotic fluid Δ OD 450 can also be plotted in other charts (Queenan, extended Liley) or be used as Ovenstone factor, or transmutance ratio.⁵⁻⁸

The invasive nature of amniocentesis remains a disadvantage, however. With each procedure, there is a risk of iatrogenic rupture of the fetal membranes or infection, both of which can lead to fetal loss. There is also the risk of increasing severity of sensitization by either boosting of antibody titer or formation of additional antibodies.⁹ Since the introduction of non-invasive methods to diagnose fetal anemia, the evaluation of the diagnostic performance of invasive Δ OD 450 measurement is now warranted.^{10;11}

Sonographic prediction of severe anemia is easy when the fetus is hydropic. However, treatment results are definitely worse in hydropic than in non-hydropic fetuses.¹² Therefore, severe fetal anemia should preferably be diagnosed and treated before hydrops develops. During the last decade, different methods for this purpose have been proposed: sonographic liver^{13;14} and spleen¹⁵ measurements, Doppler measurements of the middle cerebral artery¹⁰, intrahepatic umbilical vein^{16;17}, descending aorta¹⁸, splenic artery¹⁹ or combined measurements.^{11;20} Of these methods, measurement of Middle cerebral artery (MCA) peak systolic velocity is the most widely used. An increased peak systolic velocity in the MCA as

predictor of severe fetal anemia was first described by Mari et al.²¹ It is thought that this increase in systolic velocity is caused by a hyperdynamic circulation with increased contractility of the heart and decreased viscosity of the blood.¹⁸ In a prospective series, Mari et al., established the normal median for MCA peak systolic velocity throughout gestation and drew the demarcation line between moderate and severe anemia around 1.5 MoM.¹⁰

We aimed to compare the accuracy of amniotic fluid Δ OD 450 with the accuracy of the more recent non-invasive Doppler measurement of MCA peak systolic velocity. Therefore we performed a literature review on the accuracy of, first, Δ OD 450 and, second, MCA peak systolic velocity. We calculated the sensitivities and specificities for the different cut-offs used in each study.

Methods

Δ OD 450

English language journals indexed in Medline between 1961 and 2003 were searched for articles addressing amniotic fluid bilirubin levels in the management of red cell alloimmunization. Search terms included “rhesus”, “Liley”, “Queenan”, “OD 450”, “amniotic bilirubin”, and “amniotic optical density”. Selected abstracts were reviewed for relevant information on the test characteristics of amniotic fluid Δ OD 450 to predict fetal anemia. The references of retrieved articles were reviewed for additional articles not identified through the database search. Data on hydropic fetuses were excluded. Two groups were recognized. The first group describes test characteristics of amniotic fluid Δ OD 450 in the prediction of fetal anemia at fetal blood sampling. The second group describes test characteristics of amniotic fluid Δ OD 450 in the prediction of fetal anemia at birth. Sensitivity, specificity, and overall accuracy (combined rate of true-positive and true-negative results) were calculated for different Δ OD 450 cut-offs in the prediction of anemia by two of the authors (ES and FV).

MCA peak systolic velocity

We also searched English language journals indexed in Medline between 1995 and 2005 addressing MCA peak systolic velocity in predicting fetal anemia. The following search term was used: “middle cerebral artery and fetal anemia”. Selected abstracts were reviewed for relevant information on the test characteristics of MCA peak systolic velocity to predict fetal anemia. The references of retrieved articles were reviewed for additional articles not identified through the database search. Sensitivity and specificity were calculated for different MCA cut-offs in the prediction of anemia by two of the authors (ES and FV).

Simultaneous Δ OD 450 and MCA peak velocity

In addition, the search consisted of English language journals indexed in Medline between 1995 and 2005 addressing both Δ OD 450 and MCA peak systolic velocity in predicting fetal anemia. The following search term was used: “amniocentesis and middle cerebral artery”. Selected abstracts were reviewed for relevant information on the test characteristics of both Δ OD 450 and MCA peak systolic velocity to predict fetal anemia in the same patient population. The references of retrieved articles were reviewed for additional articles not identified through the database search. Sensitivity, specificity, and overall accuracy (combined rate of true-positive and true-negative results) were calculated by two of the authors (ES and FV).

Results

Studies with test characteristics of Δ OD 450

The literature search resulted in 73 abstracts. In 28 papers, test characteristics were mentioned and these papers were read in detail. Twelve additional papers were found by checking the references of these papers. Finally, five papers compared Δ OD 450 with hemoglobin concentration obtained by fetal blood sampling and gave sufficient data to calculate test characteristics.²²⁻²⁶ All patients in these studies were rhesus-D immunized. These papers are listed in Table I. Sensitivities of Liley’s zone III and Queenan’s zone 4 in the prediction of severe anemia (not uniformly

Table 1 - Test characteristics of amniotic fluid Δ OD 450 in the prediction of fetal anti-rhesus D alloimmune anemia at fetal blood sampling (non-hydrotic fetuses)

First author, Number of patients, year	Number of amnio centeses	Range of gestational age (weeks)	Test cut-off	Definition of	Sensitivity (%)	Specificity (%)	Accuracy (%)
Nicolaides, ²³ 1986	45	45 < 26	Extrapolated Zone III	Hb < 6 g/dl	47	82	69
		Liley Zone IIB			94	43	62
			Zone III Hb < 9.7 g/dl		38	92	53
			Zone IIB		84	62	78
MacKenzie, ²² 1988	36	63	17 - 35	Extrapolated Zone III Ht < 25 (17-25 weeks)	--	--	79
		Liley		Ht < 30 (25-35 weeks)			
Rahman, ²⁴ 1998	43	43 < 27	Queenan Zone 4	Ht < 15 %	33	36	35
			Zone 3		80	7	33
			Zone 4	Ht < 30 %	44	22	40
			Zone 3		88	11	72
Scott, ²⁵ 1998	35	72	16 - 38	Queenan Zone 4 Hb-deficit > 7 g/dl	100	79	81
			Zone 3		100	38	42
			Zone 4	Hb-deficit > 2 g/dl	88	95	93
			Zone 3		100	47	60
	--	36	27 - 38	Liley Zone III Hb-deficit > 7 g/dl	--	92	92
				Zone III Hb-deficit > 2 g/dl	100	97	97
Sikkel, ²⁶ 2002	79	79	20 - 35	Extrapolated Zone III Hb-deficit > 5 g/dl	79	50	75
			Liley Zone IIc		97	25	86
	24	24 < 27		Zone III	74	100	79
				Zone IIc	95	60	88
	55	55	≥ 27	Liley Zone III	81	14	73
				Zone IIc	98	0	85

Hb: Hemoglobin concentration, Ht: Hematocrit, --: not given

Hb-deficit: Difference between actual Hb and mean Hb for corresponding gestational age

defined) ranged from 33% to 100%. Sensitivities of the upper half of Liley's zone II (IIB) or Queenan's zone 3 ranged from 80% to 100%. Table 2 lists another 12 studies, where Δ OD 450 was compared with the severity of clinically defined fetal anemia or hemoglobin concentration at birth.^{3;5-8;27-33} Although the majority of patients in these studies were rhesus-D immunized, other antibodies (including anti-Kell) may have played a role in some of the patients. In case of anti-Kell antibodies, anemia may be partially caused by erythroid precursor damage and not merely by hemolysis. Consequently, the haemolytic-induced rise in amniotic fluid bilirubin may be less pronounced in case of anti-Kell antibodies and severe anemia may remain undetected.³⁴⁻³⁶

Studies with test characteristics of MCA peak systolic velocity

This literature search resulted in 75 abstracts. In 32 papers, test characteristics were mentioned and these papers were read in detail. There were no additional papers found by checking the references of these papers. Finally, 14 papers compared MCA peak systolic velocity with fetal hemoglobin concentration at fetal blood sampling or at birth and gave sufficient data to calculate test characteristics.^{10;20;37-48} These papers are listed in Table 3. Sensitivities of MCA peak systolic velocity in the prediction of severe anemia (according to different definitions) ranged from 31% to 100%.

Studies with test characteristics of both Δ OD 450 and MCA peak systolic velocity in the same fetuses

Our search resulted in 12 abstracts. In 3 papers, test characteristics were mentioned and these papers were read in detail. One additional paper was found by checking the references of these papers. Finally, three papers compared Δ OD 450 and MCA peak systolic velocity with hemoglobin concentration and gave sufficient data to calculate test characteristics.⁴⁹⁻

⁵¹ These papers are listed in Table 4. Sensitivities of Δ OD 450 in the prediction of severe anemia (according to different definitions) ranged from 53% to 86%. Sensitivities of MCA peak systolic velocity in the prediction of severe anemia (according to different definitions) ranged from 64% to 100%.

Table 2 - Test characteristics of amniotic fluid Δ OD 450 in the prediction of neonatal anemia at birth.

First author, Number of patients	Number of amniocenteses	Range of gestational age (weeks)	Test cut-off	Definition of	Sensitivity (%)	Specificity (%)	Accuracy (%)
Liley, ³ 1961	47	27 - 38	Liley	Zone III Hb < 11 g/dl	76	89	79
				Zone IIc	87	67	83
Pridmore, ⁷ 1972	716	20 - 39	Transmittance ratio	Hb < 7.5 g/dl or death	--	--	89
Bosch, ²⁷ 1974	312	312	≥ 26	Liley	Zone III Hb < 11 g/dl	80	98 91
Bowman, ⁵ 1975	928	215 - 37	Extrapolated	Liley	Zone III hydrops fetalis or need for treatment	91	99 97
MacDougall, ³⁰ 1975	173	173	--	Liley	Zone III Hb < 10 g%	33	100 88
Fairweather, ²⁹ 1976	141	21 - 39	Δ OD 450 <30 wks: >0.25 >30 wks: >0.15	Hb < 7.5 g/dl	72	91	85
Robertson, ³¹ 1976	288	28 - 35	Bilirubin ratio > 1.1 or stillbirth	Hb < 7.4 g/dl	69	86	82
Moore, ⁶ 1977	46	24 - 40	Liley	Zone III death or multiple transfusions	50	100	85
			Ovenstone factor > 30	Zone IIb exchange transfusions	71	88	83
				> 20	36	100	80
					64	100	89
Weiner, ³³ 1981	56	158	--	Liley	Zone B'' fetal demise or need for neonatal transfusion	67	90 79
Skjaeraasen, ³² 1983	71	72	26 - 32	Δ OD 450 >0.3	intrauterine or neonatal death	86	71 79
Ananth, ²⁸ 1989	32	41	16 - 20	Δ OD450 >0.15	fetal death or IUT or exchange transfusion	59	95 76
Queenan, ⁸ 1993	74	163	16 - 36	Queenan Zone 4 "Potentially fatal"	100	100	100

Hb: Hemoglobin concentration, --: not given. IUT: Intrauterine transfusion

Table 3 - Test characteristics of MCA peak systolic velocity in the prediction of fetal anemia at fetal blood sampling or at birth.

<i>First author year</i>	<i>Number of measurements</i>	<i>Number of anemic fetuses</i>	<i>Number of Test cut-off Definition of Sensitivity</i>	<i>Specificity Study design anemia</i>	<i>(%) (%)</i>
Mari, ¹⁰ 2000	111	35	12 1.5 MoM Hb < 0.65 MoM	100 88 retrospectively, cut-off drawn at 100 % sensitivity	
Teixera, ⁴⁶ 2000	26	13	1 > 2 SD above z the mean	_Ht < -4	67 90 prospective
Delle Chiaie, ³⁹ 2001	140	108	1 1.29 MoM Hb < 0.84 MoM	73 82 --	
Deti, ⁴¹ 2001	64	11	4 1.69 MoM Hb < 0.55 MoM	100 94 cut-off drawn at 100 % sensitivity	
Sikkel, ²⁰ 2001	42	38	0 1.5 MoM Hb	≤ -5 SD	71 50 prospective
Deren, ⁴⁰ 2002	103	53	0 1.35 MoM Hb < 0.6 MoM	100 82 prospective	
Zimmerman, ⁴⁸ 2002	125	15	3 1.5 MoM Hb < 0.65 MoM	88 87 prospective, < 35 weeks	
Alshimmiri, ³⁸ 2003	66	29	27 1.5 MoM Hb < 0.65 MoM	31 97 prospective	
Duckler, ⁴² 2003	16	6	0 1.5 MoM Hb deficit > 5 SD	100 100 prospective	
Sikkel, ⁴⁵ 2003	60	46	12 1.5 MoM z_Ht	≤ -5 SD	54 57 prospective
Mc Lean, ⁴³ 2004	42	3	0 1.5 MoM Hb < 0.65 MoM	100 90 retrospective	
Scheier, ⁴⁴ 2004	58	23	9 1.5 MoM Hb deficit > 6 SD	96 86 cross-sectional	
Ahmed, ³⁷ 2005	65	4	0 1.5 MoM --		50 97 prospective
v Dongen, ⁴⁷ 2005	27	18	10 1.5 MoM Hb deficit > 5 SD	89 89 prospective	

Hb: Hemoglobin concentration, Ht: Hematocrit, MCA: Middle cerebral artery, MoM: Multiples of the median value for gestational age in normal fetuses, SD: Standard deviation, --: not given

Table 4 - Test characteristics of Δ OD 450 and MCA peak systolic velocity in the prediction of fetal anemia in the same patients.

First author year of publication	Number of severely anemic fetuses	Number fetuses	Definition MCA sensitivity	Cut-off specificity	MCA cut-off accuracy				Δ OD 450 sensitivity	Δ OD 450 specificity	Δ OD 450 accuracy	Study design
								(%)	(%)	(%)		
Nishie, ⁵¹ 2003	28	7	Hb deficit > -5 SD	> 1.5 MoM	100	65	73	Bowman's curve	86	100	96	prospective
Pereira, ⁵⁰ 2003	28	4	Hb < 0.55 MoM	> 1.5 MoM	100	88	89	Liley high zone 2	75	75	75	retrospective or zone 3
Bullock, ⁴⁹ 2005	38	22	Hb < 5th percentile	> 1.5 MoM	64	81	71	Liley curve "over the action line"	53	71	59	cross-sectional

Hb: Hemoglobin concentration, MCA: Middle cerebral artery, MoM: Multiples of the median value for gestational age in normal fetuses, SD: Standard deviation.

Discussion

This study shows that sensitivities to predict severe anemia at fetal blood sampling (Table 1) were between 80 % and 100% for Δ OD 450 in the upper half of Liley's zone II (IIB) or Queenan's zone 3. These results are excellent, because the procedure-related risk of amniocentesis is low compared to the procedure-related risk of fetal blood sampling. The sensitivities of Δ OD 450 in the prediction of neonatal anemia at birth (Table 2) were much more variable. This is readily explained by the commonly longer time period between amniocentesis and birth. Also, it should be noted that different inclusion criteria and different definitions of severe anemia were used in the different studies.

The ACOG recommends diagnostic amniocentesis for red cell alloimmunization with high antibody titers from as early as 20 weeks gestation and therapeutic intervention when Δ OD 450 is in Liley's zone 3 or rising in the upper third of zone 2.⁴ The results of our previous study support this guideline: a 95 % sensitivity for severe fetal anemia was found.²⁶ However, a specificity of 50% and the risk associated with repeated amniocentesis remain the major drawbacks of this approach. In addition, fetal and perinatal procedure-related loss rates are reported to be 0.25 to 1% per amniocentesis.^{52;53} Further, false positive results of amniocentesis can lead to unnecessary IUTs with procedure-related fetal loss rates of 1 to 3%.⁵⁴ Finally, another drawback of amniocentesis or fetal blood sampling is the risk of feto-maternal hemorrhage that may increase the severity of alloimmunization. Feto-maternal hemorrhage occurs in 2.3% of cases after amniocentesis.⁹ A significant increase in antibody titers and induction of additional antibodies occurs in respectively 50% and 26% of cases after IUT.^{9;55;56} Thus, there is still a need for non-invasive tests that can predict fetal anemia with equal or higher accuracy.

Recent studies suggest that arterial and venous Doppler flow velocities in fetal vessels accurately predict anemia.^{10;46;57;58} These studies report that Doppler measurements, when performed by experienced operators, have sensitivities between 67% and 100% and specificities between 70% and 100% in the prediction of severe fetal anemia.^{10;46;57;58} However, there is a

tendency to be overly optimistic about early results with new techniques. In the present study, we also performed a literature review on the accuracy of Doppler measurements of MCA peak systolic velocity in the prediction of severe fetal anemia. The selected studies showed sensitivities and specificities that were comparable to those reported in the Δ OD 450 studies.

In three small studies, each with less than 40 patients, Doppler and Δ OD 450 were compared.⁴⁶⁻⁴⁸ Two of these studies were retrospective, only one was prospective. In these studies, the accuracy of MCA peak systolic velocity was better than that of Δ OD 450.

From our literature review, we conclude that Δ OD 450 measurement predicts severe anemia with sensitivities ranging between 80 and 100 % in most studies. In recently published series on MCA Doppler velocimetry, sensitivities for the prediction of severe fetal anemia range between 54 and 100 %. It is still unknown which test, the traditional minimally invasive amniocentesis with Δ OD 450 measurements, or the more recent non-invasive MCA Doppler measurements, is the more accurate. Only a prospective trial, comparing the characteristics of the two tests (Δ OD 450 and MCA peak systolic velocity) simultaneously measured in the same patients, with the gold standard test (fetal hemoglobin concentration) can provide the answer. We have been engaged in such a trial, called the DIAMOND (“diagnostic amniocentesis or non-invasive Doppler”) study and the results of this trial will become available soon.⁵⁹

References

1. Sikkell E, Pasman SA, Oepkes D, Kanhai HH, Vandenbussche FP. On the origin of amniotic fluid bilirubin. *Placenta* 2004;25:463-68.
2. Bevis DC. Blood pigments in haemolytic disease of the newborn. *J. Obstet. Gynaecol.Br. Emp.* 1956;63:68-75.
3. Liley AW. Liquor amnii analysis in the management of the pregnancy complicated by rhesus sensitization. *Am. J. Obstet. Gynecol.* 1961;82:1359-70.
4. American College of Obstetricians and Gynecologists. Management of isoimmunization in pregnancy. ACOG technical bulletin no.227.Washington, DC: American College of Obstericians and Gynecologists 1996.
5. Bowman JM. Rh erythroblastosis fetalis 1975. *Semin.Hematol.* 1975;12:189-207.
6. Moore GI, Hochberg CJ. Ovenstone Factor in the management of Rh sensitization. *South. Med. J.* 1977;70:1093-95.
7. Pridmore BR, Robertson EG, Walker W. Liquor bilirubin levels and false prediction of severity in rhesus haemolytic disease. *Br. Med. J.* 1972;3:136-39.
8. Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. *Am. J. Obstet. Gynecol.* 1993;168:1370-76.
9. Bowman JM, Pollock JM. Transplacental fetal hemorrhage after amniocentesis. *Obstet. Gynecol.* 1985;66:749-54.
10. Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ, Jr. et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. *N. Engl. J. Med.* 2000;342:9-14.
11. Oepkes D, Brand R, Vandenbussche FP, Meerman RH, Kanhai HH. The use of ultrasonography and Doppler in the prediction of fetal haemolytic anaemia: a multivariate analysis. *Br. J. Obstet. Gynaecol.* 1994;101:680-84.
12. van Kamp IL, Klumper FJ, Bakkum RS, Oepkes D, Meerman RH, Scherjon SA et al. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. *Am. J. Obstet. Gynecol.* 2001;185:668-73.
13. Roberts AB, Mitchell JM, Pattison NS. Fetal liver length in normal and isoimmunized pregnancies. *Am. J. Obstet. Gynecol.* 1989;161:42-46.
14. Vintzileos AM, Campbell WA, Storlazzi E, Mironchnick MH, Escoto DT, Nochimson DJ. Fetal liver ultrasound measurements in isoimmunized pregnancies. *Obstet. Gynecol.* 1986;68: 162-67.
15. Oepkes D, Meerman RH, Vandenbussche FP, van Kamp IL, Kok FG, Kanhai HH. Ultrasonographic fetal spleen measurements in red blood cell-alloimmunized pregnancies. *Am. J. Obstet. Gynecol.* 1993;169:121-28.
16. Gill RW, Kossoff G, Warren PS, Garrett WJ. Umbilical venous flow in normal and complicated pregnancy. *Ultrasound Med. Biol.* 1984;10:349-63.
17. Kirkinen P, Jouppila P, Eik-Nes S. Umbilical vein blood flow in rhesus-isoimmunization. *Br. J. Obstet. Gynaecol.* 1983;90:640-43.
18. Nicolaides KH, Bilardo CM, Campbell S. Prediction of fetal anemia by measurement of the mean blood velocity in the fetal aorta. *Am. J. Obstet. Gynecol.* 1990;162:209-12.

19. Bahado-Singh R, Oz U, Deren O, Pirhonen J, Kovanci E, Copel J et al. A new splenic artery Doppler velocimetric index for prediction of severe fetal anemia associated with Rh alloimmunization. *Am. J. Obstet. Gynecol.* 1999;180:49-54.
20. Sikkel, E., Oepkes, D., Meerman, R. H., and Vandenbussche, F. P. Combined arterial and venous Doppler to improve prediction of fetal anemia. *Am. J. Obstet. Gynecol.* 185, S260. 2001.
21. Mari G, Adrignolo A, Abuhamad AZ, Pirhonen J, Jones DC, Ludomirsky A et al. Diagnosis of fetal anemia with Doppler ultrasound in the pregnancy complicated by maternal blood group immunization. *Ultrasound Obstet. Gynecol.* 1995;5:400-05.
22. Mackenzie IZ, Bowell PJ, Castle BM, Selinger M, Ferguson JF. Serial fetal blood sampling for the management of pregnancies complicated by severe rhesus (D) isoimmunization. *Br. J. Obstet. Gynaecol.* 1988;95:753-58.
23. Nicolaides KH, Rodeck CH, Mibashan RS, Kemp JR. Have Liley charts outlived their usefulness? *Am. J. Obstet. Gynecol.* 1986;155:90-94.
24. Rahman F, Detti L, Ozcan T, Khan R, Manohar S, Mari G. Can a single measurement of amniotic fluid delta optical density be safely used in the clinical management of Rhesus-alloimmunized pregnancies before 27 weeks' gestation? *Acta Obstet. Gynecol. Scand.* 1998;77:804-07.
25. Scott F, Chan FY. Assessment of the clinical usefulness of the 'Queenan' chart versus the 'Liley' chart in predicting severity of rhesus iso-immunization. *Prenat. Diagn.* 1998;18: 1143-48.
26. Sikkel E, Vandenbussche FP, Oepkes D, Meerman RH, Le Cessie S, Kanhai HH. Amniotic fluid Delta OD 450 values accurately predict severe fetal anemia in D-alloimmunization. *Obstet. Gynecol.* 2002;100:51-57.
27. Bosch EG, Robinson JE, Fisher CC. The liquor amnii bilirubin-protein ratio in the management of Rhesus isoimmunization. *Med. J. Aust.* 1974;2:556-59.
28. Ananth U, Queenan JT. Does midtrimester delta OD450 of amniotic fluid reflect severity of Rh disease? *Am. J. Obstet. Gynecol.* 1989;161:47-49.
29. Fairweather DV, Whyley GA, Millar MD. Six years' experience of the prediction of severity in rhesus haemolytic disease. *Br. J. Obstet. Gynaecol.* 1976;83:698-706.
30. MacDougall JY, Black MD. Assessment of severity of haemolytic disease of the newborn at time of birth. *Scott. Med. J.* 1975;20:35-36.
31. Robertson EG, Brown A, Ellis MI, Walker W. Intrauterine transfusion in the management of severe rhesus isoimmunization. *Br. J. Obstet. Gynaecol.* 1976;83:694-97.
32. Skjaeraasen J, Moe N. Intra-uterine transfusions to the Rhesus-immunized fetus in the Department of Obstetrics, National Hospital, Oslo 1968-1979. The fetal prognosis by intra-uterine transfusions in relation to amniotic fluid blood pigment index. *Acta Obstet. Gynecol. Scand.* 1983;62:349-52.
33. Weiner S, Bolognese RJ, Librizzi RJ. Ultrasound in the evaluation and management of the isoimmunized pregnancy. *J. Clin. Ultrasound* 1981;9:315-23.
34. Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. *Am. J. Obstet. Gynecol.* 1994;171:247-52.
35. Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. *Am. J. Obstet. Gynecol.* 1996;174:547-51.

36. Leggat HM, Gibson JM, Barron SL, Reid MM. Anti-Kell in pregnancy. *Br. J. Obstet. Gynaecol.* 1991;98:162-65.
37. Ahmed B, Ghaffari Z, Ismail RS, Saleh N. Non-invasive diagnosis of fetal anemia due to maternal red-cell alloimmunization. *Saudi. Med. J.* 2005;26:256-59.
38. Alshimmiri MM, Hamoud MS, Al Saleh EA, Mujaibel KY, Al Harmi JA, Thalib L. Prediction of fetal anemia by middle cerebral artery peak systolic velocity in pregnancies complicated by rhesus isoimmunization. *J. Perinatol.* 2003;23:536-40.
39. Delle Chiaie L., Buck G, Grab D, Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. *Ultrasound Obstet. Gynecol.* 2001;18:232-36.
40. Deren O, Onderoglu L. The value of middle cerebral artery systolic velocity for initial and subsequent management in fetal anemia. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2002;101:26-30.
41. Detti L, Oz U, Guney I, Ferguson JE, Bahado-Singh RO, Mari G. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. *Am. J. Obstet. Gynecol.* 2001;185:1048-51.
42. Dukler D, Oepkes D, Seaward G, Windrim R, Ryan G. Noninvasive tests to predict fetal anemia: a study comparing Doppler and ultrasound parameters. *Am. J. Obstet. Gynecol.* 2003;188:1310-14.
43. McLean LK, Hedriana HL, Lanouette JM, Haesslein HC. A retrospective review of isoimmunized pregnancies managed by middle cerebral artery peak systolic velocity. *Am. J. Obstet. Gynecol.* 2004;190:1732-36.
44. Scheier M, Hernandez-Andrade E, Carmo A, Dezerega V, Nicolaides KH. Prediction of fetal anemia in rhesus disease by measurement of fetal middle cerebral artery peak systolic velocity. *Ultrasound Obstet. Gynecol.* 2004;23:432-36.
45. Sikkell E, Vandenbussche FP, Oepkes D, Klumper FJ, Teunissen KA, Meerman RH et al. Effect of an increase of the hematocrit on middle cerebral artery peak and umbilical vein maximum velocities in anemic fetuses. *Fetal Diagn. Ther.* 2003;18:472-78.
46. Teixeira JM, Duncan K, Letsky E, Fisk NM. Middle cerebral artery peak systolic velocity in the prediction of fetal anemia. *Ultrasound Obstet. Gynecol.* 2000;15:205-08.
47. van Dongen H, Klumper FJ, Sikkell E, Vandenbussche FP, Oepkes D. Non-invasive tests to predict fetal anemia in Kell-alloimmunized pregnancies. *Ultrasound Obstet. Gynecol.* 2005;25:341-45.
48. Zimmerman R, Carpenter RJ, Jr., Durig P, Mari G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to- treat. *BJOG.* 2002;109:746-52.
49. Bullock R, Martin WL, Coomarasamy A, Kilby MD. Prediction of fetal anemia in pregnancies with red-cell alloimmunization: comparison of middle cerebral artery peak systolic velocity and amniotic fluid OD450. *Ultrasound Obstet. Gynecol.* 2005;25:331-34.
50. Pereira L, Jenkins TM, Berghella V. Conventional management of maternal red cell alloimmunization compared with management by Doppler assessment of middle cerebral artery peak systolic velocity. *Am. J. Obstet. Gynecol.* 2003;189:1002-06.

←
BJOG Is niet
goed toch?

51. Nishie EN, Brizot ML, Liao AW, Carvalho MH, Toma O, Zugaib M. A comparison between middle cerebral artery peak systolic velocity and amniotic fluid optical density at 450 nm in the prediction of fetal anemia. *Am. J. Obstet. Gynecol.* 2003;188:214-19.
52. Bowman JM. The management of Rh-Isoimmunization. *Obstet. Gynecol.* 1978;52:1-16.
53. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. *Lancet* 1986;1:1287-93.
54. Klumper FJ, van Kamp IL, Vandenbussche FP, Meerman RH, Oepkes D, Scherjon SA et al. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2000;92:91-96.
55. Viator HE, Kanhai HH, Brand A. Induction of additional red cell alloantibodies after intrauterine transfusions. *Transfusion* 1994;34:970-74.
56. Bowman JM, Pollock JM, Peterson LE, Harman CR, Manning FA, Menticoglou SM. Fetomaternal hemorrhage following funipuncture: increase in severity of maternal red-cell alloimmunization. *Obstet. Gynecol.* 1994;84:839-43.
57. Iskaros J, Kingdom J, Morrison JJ, Rodeck C. Prospective non-invasive monitoring of pregnancies complicated by red cell alloimmunization. *Ultrasound Obstet. Gynecol.* 1998;11:432-37.
58. Oepkes D, Kanhai HH, Arabin B. Systematic antenatal functional evaluation in pregnancies at risk of progressive fetal anemia. In: Chervenak F.A., Kurjak A., eds. New York: Parthenon Publishing Group, 1996:423-37.
59. Oepkes, D., Vandenbussche, F. P., Kingdom, J., Windrim, R., Beyene, J, Kanhai, H. H., Ohlsson, A, and Ryan, G. Minimally invasive management of rh alloimmunization: Can amniotic fluid DELTA OD450 be replaced by Doppler studies? a prospective multicenter trial. *Am. J. Obstet. Gynecol.* 191(6), S2. 2004.